Search
-
Reno Home to "Great Psychiatry and Mental Health Program;" Renown and UNR School of Medicine Named to Becker's National List
Becker’s list of Hospitals and Health Systems with Great Psychiatry and Mental Health Programs for 2023 has been published, recognizing professional healthcare leaders across the country. Renown Health and the University of Nevada, Reno School of Medicine have been recognized among the top programs in the United States. This acknowledgement reflects a commitment from a dedicated team of experienced local professionals providing comprehensive mental health services and advancing the field of psychiatry. In their announcement, Becker’s highlighted that, “In 2018, a $6 million donation (by the Stacie Mathewson Foundation), funded the creation of the Stacie Mathewson Behavioral Health & Addiction Institute at Renown Health. The institute was formed to address increased prescription drug-related mortality rates and suicide rates in northern Nevada. The department is now fully integrated with University of Nevada School of Medicine's psychiatry residency, child and adolescent psychiatry fellowship programs, and behavioral sciences and clinical psychiatry medical student training. The curriculum emphasizes the value of psychotherapy, psychopharmacology, and interventional psychiatry methods, along with primary care team integration.” Becker’s editors noted that, “Innovative public and private partnerships with the state include the SOAR early intervention treatment program for those experiencing their first episode of psychosis. A 24-hour crisis stabilization center will open in 2024 for adults with mental health or substance use issues. The Connect Washoe County mental health collaborative, part of the hospital’s community benefit program, hosts the Youth Mental Health Summit, with a number of interventions resulting in reduced use of street and prescription drugs, lower hospitalization rates due to opioid overdose, and fewer cases of intentional suicide mortality in youth.” “We are honored to be recognized as one of the top psychiatry and mental health programs in the U.S. This achievement reflects the dedication of our integrated team and our unwavering commitment to enhancing the lives of individuals and families affected by mental health challenges. We will continue to strive for excellence and address the diverse needs of individuals struggling with behavioral health issues, said Takesha Cooper, MD, Department Chair of Psychiatry and Behavioral Sciences. “Our team comprises skilled psychiatrists, psychologists, therapists and support staff who collaborate to provide holistic and integrated care for our patients. As the region’s only not-for-profit health system, together with the support of grateful donors like Stacie Mathewson, we will continue to actively engage in outreach initiatives to raise awareness about mental health, reduce stigma and create a community that fosters healing and support.” Renown Health also earned Forbes' Best Healthcare Employer in Nevada for combatting burnout and ensuring well-being and safety of caregivers. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. For more information, visit renown.org. About the University of Nevada, Reno School of Medicine The University of Nevada, Reno School of Medicine (UNR Med), Nevada’s first public medical school, is a community-based, research-intensive medical school with a statewide vision for a healthy Nevada. Since 1969, UNR Med has trained more than 3,900 students, residents and fellows. UNR Med continues to improve the health and well-being of all Nevadans and their communities through excellence in student education, postgraduate training and clinical care, research with local, national and global impact and a culture of diversity and inclusion. For more information, visit med.unr.edu.
-
Exceptional Talent Joins William N. Pennington Cancer Institute at Renown; Dr. Kate Ward Brings Expertise and Vision as Vice President of Oncology Division
Renown Health is pleased to announce that Kate A. Ward, Pharm.D., BCPS, has been promoted to serve as Vice President, Oncology for Renown Regional Medical Center. Dr. Ward has over fourteen years of service to the organization, most recently as Director of Clinical Pharmacy responsible for the oversight of all clinical pharmacy activities at Renown Regional Medical Center, Renown South Meadows Medical Center, and Renown Rehabilitation Hospital. Additionally, Dr. Ward is the Residency Director of the Post-Graduate Year 1 (PGY1) Pharmacy Practice Residency at Renown. Over the last decade at Renown, Dr. Ward has served as Pharmacy Clinical Manager, Pharmacy Clinical Coordinator and Clinical Pharmacist. Dr. Ward will bring her pharmacy clinical service experience (including ICU, Outpatient Infusion, Pediatrics, Oncology and Emergency Services), Inpatient Care, Clinical Research, and Hospital Formulary Management, Electronic Medical Record Integration and Optimization to this important new role. As a dyad partner with Max J. Coppes, MD, PhD, MBA, Director of the William N. Pennington Cancer Institute at Renown, she will bring her clinical, operational, regulatory, and administrative experience to lead the oncology division. Dr. Ward, Dr. Coppes and the dedicated team will advance Renown’s mission to expand care, prevention, screening, research, and education with the goal of establishing the first National Institutes of Health, NCI designated Cancer Center for our State. “We are thrilled to welcome Dr. Ward as our new Vice President of Oncology. She brings a wealth of experience and a passion for advancing patient care. Dr. Ward will play a pivotal role in sharing the future our oncology division and furthering our commitment to providing exceptional care,” said Chris Nicholas, CEO of Renown Regional Medical Center. As a licensed pharmacist, Dr. Ward holds a Doctor of Pharmacy degree from the University of Colorado, Health Sciences Center. The Pharm.D. is a professional degree like a Doctor of Medicine (MD) or Doctor of Dental Surgery (DDS). As a doctorate, it represents the increasing responsibility pharmacists have in healthcare systems and the high trust Americans have in pharmacists. Dr. Ward completed her residency at Stanford Hospital and Clinics. She graduated from the University of Nevada, Reno with her bachelor’s degree in Nutritional Sciences. Dr. Ward is active in several professional associations and currently serves as a Pharmacy Board member for HealthTrust; Vice Chair of the American Society of Health System Pharmacists® Council on Therapeutics; and Vice Chair for the Silver State Scripts Board for the State of Nevada. Dr. Ward was the 2022 recipient of the Nevada Society of Health System Pharmacists (NVSHP) President’s Award. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. To join the Renown Health team, visit renown.org/careers.
-
Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results
Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively. Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively. “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.” The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.